🔗 Share this article

As the US proceeds with sweeping changes to its vaccination recommendations, an unexpected name appears somewhat surprisingly: Høeg, a US-based physician and public health researcher who rose to prominence by casting doubt on COVID-19 shots in the pandemic and has focused upon potential fatalities following Covid immunization in her brief tenure at the Food and Drug Administration.

Proposed Shifts to Childhood Vaccine Program

Agency leaders had intended to reveal major revisions to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s immunization schedule, sources say – a major change that would put the US out of step with much of the world with no evidence for improved outcomes. This reveal has been delayed until the coming year.

In place of the top vaccines chief, Høeg is listed to address the audience at the gathering. She was recently named acting director of the FDA’s CDER, the fifth person to head the center this calendar year.

A New Direction at the Regulatory Body

This interim role might represent a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a renewed priority upon reevaluating already-approved vaccines at the FDA.

Høeg has often pushed for discontinuing some pediatric immunization guidelines in the US in order to be more like the Danish model, a society with comprehensive healthcare and a population about the population of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccination policy – typically the domain of Prasad, director of the FDA’s CBER – rather than drug regulation.

Questions Over Background

The appointee has no apparent experience in pharmaceutical research, oversight or leadership, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for leading the CDER, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with legal statutes and the underlying principles of drug development”, said a former acting FDA commissioner. “Frankly, she lacks the sort of resume that previous people who ran CBER have had.”

This division has an vast workload at the FDA, she pointed out.

“Many people just zeroes in on the new drug program, but the generic program authorizes thousands of generic medications. There’s a biologic copycat branch, over-the-counter program and more, and every single one have to be looked after,” Dr. Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial leadership aspect to the role, which oversees more than 5,000 staff members. “It’s a enormous leadership role, if you execute it properly,” she concluded.

Response and Contentious Policies

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment represents increased cooperation among agency officials on vaccines, a press secretary stated that the “questions are based on flawed assumptions”.

“This background is consistent with the responsibilities of her role,” the official said, pointing to the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg takes over the commissioner’s new fast-track approval initiative, a controversial rapid therapy clearance system that apparently concerned her preceding directors. “How are these medications being selected for this voucher program? Who is making the calls?” Howard questioned. “There is a lot of confidentiality happening at the FDA right now.”

Overall, he stated, “the FDA looks to be trending towards less stringent regulations of all drugs, with the exception of vaccines.”

Documented History on Immunizations

Concerning immunizations, Høeg has a more established, if troubling, history, Howard said. She released a research paper using unverified crowd-sourced reports to estimate the frequency of myocarditis after COVID-19 immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the incoming federal leadership included revising guidelines for recently developed shots and ending “optional” vaccines, she said after the election on a audio program. At the FDA, Høeg has allegedly proposed excluding adolescent males from obtaining COVID-19 vaccinations.

“She’s an all-around true believer who commences with her conclusions and tailors the evidence to retrofit the data in a highly misleading, fraudulent fashion,” Howard said.

Taking Control and a “Push for Payback”

Høeg became part of other dissenters, {like|